HUMEDIX revenue for the last year amounted to 152.15 B KRW, the most of which — 114.80 B KRW — came from its highest performing source at the moment, Hyaluronic Acid-based Medical Devices (Fillers) and Arthritis Therapies Product, the year earlier bringing 91.27 B KRW. The greatest contribution to the revenue figure was made by South Korea — last year it brought HUMEDIX 125.80 B KRW, and the year before that — 103.96 B KRW.